ABBOTT RAPID DIAGNOSTICS

Abbott is a global leader in rapid diagnostic tests that deliver the right care, at the right time. Our comprehensive portfolio of tests for infectious disease, cardiometabolic disease and toxicology provide fast, reliable and actionable information that help improve quality of care and enable better clinical and economic health outcomes. In 2017, we delivered more than one billion tests to healthcare professionals and patients around the world.

ACCELERATE DIAGNOSTICS

Hospitals are increasingly encountering unpredictable resistance patterns clinically whilst being faced with the need to minimise broad-spectrum antibiotic use to prevent and reduce antimicrobial resistance. For patients with sepsis, time to effective and optimised therapy is critical.

Accelerate Diagnostics is an in-vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and Healthcare Associated Infections. The company’s fully automated ID/AST system, Accelerate Pheno™, and direct from positive blood culture kit, Accelerate PhenoTest™ BC, utilise proprietary molecular and phenotypic detection technologies which have the potential to substantially reduce the time to definitive, actionable antimicrobial susceptibility and MIC results by 1 to 2 days, compared with conventional methods.

Rapid ID/AST diagnostics with the Accelerate PhenoTM System allow institutions to:
• Escalate to effective therapy sooner
• Optimise and de-escalate therapy earlier
• Improve patient outcomes and reduce healthcare costs
• Support your antimicrobial stewardship efforts
• Reduce antibiotic resistance
• Decrease C. difficile risk

MSD

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.

PFIZER

Today, Pfizer UK offers patients access to a diverse portfolio of over 20 antibacterial and antifungal medicines. More than ever, the world needs new approaches to preventing and fighting infections.
Pfizer joined with over 100 industry partners to sign the Declaration on Combating Antimicrobial Resistance, announced in January 2016 at Davos, to call on governments to join industry in taking swift, coordinated action to help fight antimicrobial resistance. Pfizer sponsors the most comprehensive global antimicrobial resistance surveillance program in the industry. These programmes provide critical data regarding antibiotic resistance patterns that enable physicians and healthcare providers to make the most appropriate treatment choices for their patients. The goals of these programmes are to provide important information on resistance and to assess antibiotic stewardship.

Pfizer routinely sponsors and conducts medical education outreach to healthcare providers through a variety of channels, including medical symposia, to ensure appropriate utilisation of antibiotics and improve infection prevention and control.